TitleEnhanced delivery of peptide-morpholino oligonucleotides with a small molecule to correct splicing defects in the lung.
Publication TypeJournal Article
Year of Publication2021
AuthorsDang, Y, van Heusden, C, Nickerson, V, Chung, F, Wang, Y, Quinney, NL, Gentzsch, M, Randell, SH, Moulton, HM, Kole, R, Ni, A, Juliano, RL, Kreda, SM
JournalNucleic Acids Res
Date Published2021 06 21
KeywordsAnimals, Cells, Cultured, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Humans, Lung, Mice, Morpholinos, Mutation, Peptides, Respiratory Mucosa, RNA Splicing, Transfection

Pulmonary diseases offer many targets for oligonucleotide therapeutics. However, effective delivery of oligonucleotides to the lung is challenging. For example, splicing mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) affect a significant cohort of Cystic Fibrosis (CF) patients. These individuals could potentially benefit from treatment with splice switching oligonucleotides (SSOs) that can modulate splicing of CFTR and restore its activity. However, previous studies in cell culture used oligonucleotide transfection methods that cannot be safely translated in vivo. In this report, we demonstrate effective correction of a splicing mutation in the lung of a mouse model using SSOs. Moreover, we also demonstrate effective correction of a CFTR splicing mutation in a pre-clinical CF patient-derived cell model. We utilized a highly effective delivery strategy for oligonucleotides by combining peptide-morpholino (PPMO) SSOs with small molecules termed OECs. PPMOs distribute broadly into the lung and other tissues while OECs potentiate the effects of oligonucleotides by releasing them from endosomal entrapment. The combined PPMO plus OEC approach proved to be effective both in CF patient cells and in vivo in the mouse lung and thus may offer a path to the development of novel therapeutics for splicing mutations in CF and other lung diseases.

Alternate JournalNucleic Acids Res
PubMed ID34107015
PubMed Central IDPMC8216463
Grant ListP30 CA016086 / CA / NCI NIH HHS / United States
R41 TR001330 / TR / NCATS NIH HHS / United States
R44 TR002692 / TR / NCATS NIH HHS / United States
R41 TR002692 / TR / NCATS NIH HHS / United States
P30 DK065988 / DK / NIDDK NIH HHS / United States